Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.
Marine derived bioactive compounds for treatment of Alzheimer’s disease
*Author to whom correspondence should be addressed.
Alzheimer’s disease (AD ) is mounting as social and economic encumbrance which are accompanied by deficits in cognition and memory. Over the past decades, Alzheimer’s disease (AD) holds the frontline as one of the biggest healthcare issues in the world. AD is an age related neurodegenerative disorder marked by a decline in memory and an impairment of cognition. Inspite of tedious scientific effort, AD is still devoid of pharmacotherapeutic strategies for treatment as well as prevention. Current treatment strategies using drugs are symbolic in nature as they treat disease manifestation though are found effective in treating cognition. Inclination of science towards naturopathic treatments aiming at preventing the disease is highly vocal. Application of marine-derived bioactive compounds, has been gaining attention as mode of therapies against AD. Inspired by the vastness and biodiversity richness of the marine environment, role of marine metabolites in developing new therapies targeting brain with special emphasis to neurodegeneration is heading as an arable field. This review summarizes select-few examples highlighted as therapeutical applications for neurodegenerative disorders with special emphasis on AD.